639 related articles for article (PubMed ID: 15374979)
1. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
Ren W; Strube R; Zhang X; Chen SY; Huang XF
Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
[TBL] [Abstract][Full Text] [Related]
2. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer.
Hall SJ; Sanford MA; Atkinson G; Chen SH
Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645
[TBL] [Abstract][Full Text] [Related]
3. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine.
Huang XF; Ren W; Rollins L; Pittman P; Shah M; Shen L; Gu Q; Strube R; Hu F; Chen SY
Cancer Res; 2003 Nov; 63(21):7321-9. PubMed ID: 14612530
[TBL] [Abstract][Full Text] [Related]
4. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
7. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
8. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery.
Pan PY; Li Y; Li Q; Gu P; Martinet O; Thung S; Chen SH
Cancer Immunol Immunother; 2004 Jan; 53(1):17-25. PubMed ID: 12955480
[TBL] [Abstract][Full Text] [Related]
9. Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis.
Chan T; Chen Z; Hao S; Xu S; Yuan J; Saxena A; Qureshi M; Zheng C; Xiang J
Cancer Gene Ther; 2007 Apr; 14(4):409-20. PubMed ID: 17235354
[TBL] [Abstract][Full Text] [Related]
10. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N
Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 70 / MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo.
Ye J; Chen GS; Song HP; Li ZS; Huang YY; Qu P; Sun YJ; Zhang XM; Sui YF
Cancer Immunol Immunother; 2004 Sep; 53(9):825-34. PubMed ID: 15127237
[TBL] [Abstract][Full Text] [Related]
12. Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer.
Isomoto H; Ohtsuru A; Braiden V; Iwamatsu M; Miki F; Kawashita Y; Mizuta Y; Kaneda Y; Kohno S; Yamashita S
Oncol Rep; 2006 Mar; 15(3):629-35. PubMed ID: 16465423
[TBL] [Abstract][Full Text] [Related]
13. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.
Hauser H; Shen L; Gu QL; Krueger S; Chen SY
Gene Ther; 2004 Jun; 11(11):924-32. PubMed ID: 15085173
[TBL] [Abstract][Full Text] [Related]
14. Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ.
Rafiee M; Kanwar JR; Berg RW; Lehnert K; Lisowska K; Krissansen GW
Cancer Gene Ther; 2001 Dec; 8(12):974-81. PubMed ID: 11781660
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
16. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
17. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258
[TBL] [Abstract][Full Text] [Related]
18. Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice.
Warren P; Song W; Holle E; Holmes L; Wei Y; Li J; Wagner T; Yu X
Anticancer Res; 2002; 22(2A):599-604. PubMed ID: 12014627
[TBL] [Abstract][Full Text] [Related]
19. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.
Oh JY; Park MY; Kim DR; Lee JH; Shim SH; Chung JH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
Int J Mol Med; 2010 Mar; 25(3):369-76. PubMed ID: 20127041
[TBL] [Abstract][Full Text] [Related]
20. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
